MTSI Stock Analysis: MACOM Technology Solutions | NASDAQ
Semiconductors | NASDAQ, USA | Market Cap: 14.537m USD | 12M Return: 26.9% | US55405Y1001 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 479M
EPS Trend: 96.3%
Qual. Beats: 4
Rev. Trend: 98.7%
Qual. Beats: 3
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI) provides analog semiconductor solutions spanning the RF, microwave, millimeter wave, and lightwave spectrum. The company offers both standard and custom devices, including integrated circuits, multi-chip modules, diodes, amplifiers, switches, and subsystems. Its products serve three primary end markets: carrier infrastructure (5G/6G, satellite communications, long-haul/metro, and fiber-to-the-X networks), industrial and defense (radar, electronic countermeasures, and RF jammers), and multi-market applications (industrial, medical, test and measurement, and scientific). It also serves the data center market.
The company distributes its products through a direct sales force, applications engineering staff, independent sales representatives, resellers, and distributors. It operates internationally across China, Japan, Singapore, South Korea, Taiwan, and other regions, in addition to the United States. Founded in 1950 and headquartered in Lowell, Massachusetts, MACOM was formerly known as M/A-Com Technology Solutions Holdings, Inc. before adopting its current name in 2016, and completed its IPO in 2012.
- Data center optical revenue surges on AI hyperscaler buildout
- Defense segment grows on military radar and electronic warfare demand
- China tariff exposure pressures margins and end-market demand
| Net Income: 240.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -3.04 > 1.0 |
| NWC/Revenue: 57.63% < 20% (prev 91.83%; Δ -34.20% < -1%) |
| CFO/TA 0.13 > 3% & CFO 271.2m > Net Income 240.9m |
| Net Debt (-254.9m) to EBITDA (357.2m): -0.71 < 3 |
| Current Ratio: 2.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (78.4m) vs 12m ago 3.35% < -2% |
| Gross Margin: 56.56% > 18% (prev 53.28%; Δ 3.28% > 0.5%) |
| Asset Turnover: 56.09% > 50% (prev 45.27%; Δ 10.83% > 0%) |
| Interest Coverage Ratio: 44.10 > 6 (EBIT TTM 292.9m / Interest Expense TTM 6.64m) |
| A: 0.31 (Total Current Assets 1.17b - Total Current Liabilities 501.5m) / Total Assets 2.15b |
| B: -0.02 (Retained Earnings -44.3m / Total Assets 2.15b) |
| C: 0.14 (EBIT TTM 292.9m / Avg Total Assets 2.08b) |
| D: 2.54 (Book Value of Equity 1.54b / Total Liabilities 606.0m) |
| Altman-Z'' = 5.60 = AAA |
| DSRI: 1.08 (Receivables 179.1m/129.5m, Revenue 1.16b/906.8m) |
| GMI: 0.94 (GM 53.28% / 56.56%) |
| AQI: 1.02 (AQ_t 0.34 / AQ_t-1 0.33) |
| SGI: 1.28 (Revenue 1.16b / 906.8m) |
| TATA: -0.01 (NI 240.9m - CFO 271.2m) / TA 2.15b) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of November 11, 2026, the stock is trading at USD 226.48 with a total of 1,734,440 shares traded. Over the past week, the price has changed by -3.83%, over one month by -26.07%, over three months by -23.75% and over the past year by +26.94%.
Current recommended Stop Loss: 197.80 (which is 12.7% or 1.4 ATR below the current price).
MACOM Technology Solutions has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy MTSI.
- StrongBuy: 10
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 384.7 | 69.9% |
P/E Trailing = 44.1647
P/E Forward = 34.0136
P/S = 12.4893
P/B = 11.5555
P/EG = 2.0501
Revenue TTM = 1.16b USD
EBIT TTM = 292.9m USD
EBITDA TTM = 357.2m USD
Long Term Debt = 339.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 341.2m USD (from shortTermDebt, last quarter)
Debt = 408.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 37.0m
Net Debt = -254.9m USD (calculated: Debt 408.2m - CCE 663.0m)
Enterprise Value = 14.3b USD (14.5b + Debt 408.2m - CCE 663.0m)
Interest Coverage Ratio = 44.10 (Ebit TTM 292.9m / Interest Expense TTM 6.64m)
EV/FCF = 120.1x (Enterprise Value 14.3b / FCF TTM 118.9m)
FCF Yield = 0.83% (FCF TTM 118.9m / Enterprise Value 14.3b)
FCF Margin = 10.21% (FCF TTM 118.9m / Revenue TTM 1.16b)
Net Margin = 20.70% (Net Income TTM 240.9m / Revenue TTM 1.16b)
Gross Margin = 56.56% ((Revenue TTM 1.16b - Cost of Revenue TTM 505.6m) / Revenue TTM)
Gross Margin QoQ = 58.31% (prev 56.91%)
Tobins Q-Ratio = 6.65 (Enterprise Value 14.3b / Total Assets 2.15b)
Interest Expense / Debt = 1.63% (Interest Expense 6.64m / Debt 408.2m)
Taxrate = 15.84% (45.3m / 286.3m)
NOPAT = 246.5m (EBIT 292.9m * (1 - 15.84%))
Current Ratio = 2.34 (Total Current Assets 1.17b / Total Current Liabilities 501.5m)
Debt / Equity = 0.26 (Debt 408.2m / totalStockholderEquity, last quarter 1.54b)
Debt / EBITDA = -0.71 (Net Debt -254.9m / EBITDA 357.2m)
Debt / FCF = -2.14 (Net Debt -254.9m / FCF TTM 118.9m)
Total Stockholder Equity = 1.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.61% (Net Income 240.9m / Total Assets 2.15b)
RoE = 17.09% (Net Income TTM 240.9m / Total Stockholder Equity 1.41b)
RoCE = 16.74% (EBIT 292.9m / Capital Employed (Equity 1.41b + L.T.Debt 339.6m))
RoIC = 12.78% (NOPAT 246.5m / Invested Capital 1.93b)
WACC = 12.84% (E(14.5b)/V(14.9b) * Re(13.16%) + D(408.2m)/V(14.9b) * Rd(1.63%) * (1-Tc(0.16)))
Discount Rate = 13.16% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 82.46 | Cagr: 3.06%
[DCF] Terminal Value 58.33% ; FCFF base≈140.1m ; Y1≈122.8m ; Y5≈99.2m
[DCF] Fair Price = 15.41 (EV 922.0m - Net Debt -254.9m = Equity 1.18b / Shares 76.4m; r=12.84% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 96.27 | EPS CAGR: 28.73% | SUE: 4.0 | # QB: 4
Revenue Correlation: 98.68 | Revenue CAGR: 26.99% | SUE: 3.39 | # QB: 3
EPS current Quarter (2026-12-31): EPS=2.03 | Chg30d=+0.33% | Revisions=+25% | Analysts=15
EPS next Quarter (2027-03-31): EPS=2.09 | Chg30d=+0.38% | Revisions=+25% | Analysts=15
EPS current Year (2027-09-30): EPS=8.54 | Chg30d=+0.55% | Revisions=+40% | GrowthEPS=+52.4% | GrowthRev=+36.0%
EPS next Year (2028-09-30): EPS=10.11 | Chg30d=+0.55% | Revisions=-25% | GrowthEPS=+18.4% | GrowthRev=+15.9%
[Analyst] Revisions Ratio: +38% (up=4, down=1)